Benzinga's Top #PreMarket Gainers

Idera Pharmaceuticals Inc IDRA gained 6.44 percent to $3.80 in pre-market trading. JP Morgan initiated coverage on Idera Pharmaceuticals with a Overweight rating. Plasmatech Biopharmaceuticals Inc PTBI shares rose 5.05 percent to $7.70 in pre-market trading following the announcement of license deal for gene therapy in Fanconi anemia, CRISPR/Cas9-Based technology platform. bluebird bio Inc BLUE shares rose 4.98 percent to $189.82 in pre-market trading after the company reported new data from HGB-205 study. Philip Gregory, D. Phil., joined bluebird bio as Chief Scientific Officer. JP Morgan maintained bluebird bio with a Overweight and raised the price target from $200.00 to $244.00. Trivascular Technologies Inc TRIV shares climbed 3.91 percent to $7.18 in pre-market trading after the company reported the FDA approval of Ovation iX(TM) Iliac Stent Graft. Standard Pacific Corp. SPF shares climbed 1.80 percent to $8.50 in pre-market trading. Standard Pacific and Ryland Group Inc RYL agreed to merge in an all-stock transaction.